191 related articles for article (PubMed ID: 25823661)
1. The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients.
Fagerholm R; Schmidt MK; Khan S; Rafiq S; Tapper W; Aittomäki K; Greco D; Heikkinen T; Muranen TA; Fasching PA; Janni W; Weinshilboum R; Loehberg CR; Hopper JL; Southey MC; Keeman R; Lindblom A; Margolin S; Mannermaa A; Kataja V; Chenevix-Trench G; ; Lambrechts D; Wildiers H; Chang-Claude J; Seibold P; Couch FJ; Olson JE; Andrulis IL; Knight JA; García-Closas M; Figueroa J; Hooning MJ; Jager A; Shah M; Perkins BJ; Luben R; Hamann U; Kabisch M; Czene K; Hall P; Easton DF; Pharoah PD; Liu J; Eccles D; Blomqvist C; Nevanlinna H
Oncotarget; 2015 Apr; 6(10):7390-407. PubMed ID: 25823661
[TBL] [Abstract][Full Text] [Related]
2. TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.
Fagerholm R; Khan S; Schmidt MK; García-Closas M; Heikkilä P; Saarela J; Beesley J; Jamshidi M; Aittomäki K; Liu J; Ali HR; Andrulis IL; Beckmann MW; Behrens S; Blows FM; Brenner H; Chang-Claude J; Couch FJ; Czene K; Fasching PA; Figueroa J; Floris G; Glendon G; Guo Q; Hall P; Hallberg E; Hamann U; Holleczek B; Hooning MJ; Hopper JL; Jager A; Kabisch M; ; Keeman R; Kosma VM; Lambrechts D; Lindblom A; Mannermaa A; Margolin S; Provenzano E; Shah M; Southey MC; Dennis J; Lush M; Michailidou K; Wang Q; Bolla MK; Dunning AM; Easton DF; Pharoah PD; Chenevix-Trench G; Blomqvist C; Nevanlinna H
Oncotarget; 2017 Mar; 8(11):18381-18398. PubMed ID: 28179588
[TBL] [Abstract][Full Text] [Related]
3. A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.
Seibold P; Schmezer P; Behrens S; Michailidou K; Bolla MK; Wang Q; Flesch-Janys D; Nevanlinna H; Fagerholm R; Aittomäki K; Blomqvist C; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Lambrechts D; Wildiers H; Kristensen V; Alnæs GG; Nord S; Borresen-Dale AL; Hooning MJ; Hollestelle A; Jager A; Seynaeve C; Li J; Liu J; Humphreys K; Dunning AM; Rhenius V; Shah M; Kabisch M; Torres D; Ulmer HU; Hamann U; Schildkraut JM; Purrington KS; Couch FJ; Hall P; Pharoah P; Easton DF; Schmidt MK; Chang-Claude J; Popanda O
BMC Cancer; 2015 Dec; 15():978. PubMed ID: 26674097
[TBL] [Abstract][Full Text] [Related]
4. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
5. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
[TBL] [Abstract][Full Text] [Related]
6. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Modi S; Currie VE; Seidman AD; Bach AM; Panageas KS; Theodoulou M; Moasser MM; D'Andrea GM; Lake DE; Choi J; Norton L; Hudis CA
Clin Breast Cancer; 2005 Apr; 6(1):55-60. PubMed ID: 15899073
[TBL] [Abstract][Full Text] [Related]
8. Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
Cámara RJA; Schwentner L; Friedl TWP; Deniz M; Fink V; Lato K; Widschwendter P; Rack B; Janni W; Singer S; Bekes I
Breast Cancer Res Treat; 2019 Jun; 175(3):627-635. PubMed ID: 30900137
[TBL] [Abstract][Full Text] [Related]
9. LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.
Rusz O; Papp O; Vízkeleti L; Molnár BÁ; Bende KC; Lotz G; Ács B; Kahán Z; Székely T; Báthori Á; Szundi C; Kulka J; Szállási Z; Tőkés AM
Cancer Chemother Pharmacol; 2018 Jul; 82(1):139-147. PubMed ID: 29770955
[TBL] [Abstract][Full Text] [Related]
10. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
11. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
Brandi M; Vici P; Lopez M; Valerio MR; Giotta F; Gebbia N; Schittulli F; Colucci G;
Semin Oncol; 2004 Apr; 31(2 Suppl 5):13-9. PubMed ID: 15199527
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Rack B; Schindlbeck C; Jückstock J; Andergassen U; Hepp P; Zwingers T; Friedl TW; Lorenz R; Tesch H; Fasching PA; Fehm T; Schneeweiss A; Lichtenegger W; Beckmann MW; Friese K; Pantel K; Janni W;
J Natl Cancer Inst; 2014 May; 106(5):. PubMed ID: 24832787
[TBL] [Abstract][Full Text] [Related]
14. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
[TBL] [Abstract][Full Text] [Related]
15. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
Mauri D; Polyzos NP; Salanti G; Pavlidis N; Ioannidis JP
J Natl Cancer Inst; 2008 Dec; 100(24):1780-91. PubMed ID: 19066278
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
Zielinski CC
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):36-40. PubMed ID: 14768404
[TBL] [Abstract][Full Text] [Related]
17. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Swain SM; Tang G; Geyer CE; Rastogi P; Atkins JN; Donnellan PP; Fehrenbacher L; Azar CA; Robidoux A; Polikoff JA; Brufsky AM; Biggs DD; Levine EA; Zapas JL; Provencher L; Northfelt DW; Paik S; Costantino JP; Mamounas EP; Wolmark N
J Clin Oncol; 2013 Sep; 31(26):3197-204. PubMed ID: 23940225
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.
Marmé F; Aigner J; Lorenzo Bermejo J; Sinn P; Sohn C; Jäger D; Schneeweiss A
Int J Cancer; 2013 Aug; 133(4):1006-15. PubMed ID: 23400797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
